Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Thrombomodulin expressing monocytes are associated with low risk features in myelodysplastic syndromes and dampen excessive immune activation.

van Leeuwen-Kerkhoff N, Westers TM, Poddighe PJ, de Gruijl TD, Kordasti S, van de Loosdrecht AA.

Haematologica. 2019 Jul 4. pii: haematol.2019.219303. doi: 10.3324/haematol.2019.219303. [Epub ahead of print]

2.

The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?

van Spronsen MF, Westers TM, Lissenberg-Witte BI, Wondergem M, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2019 Apr 19. pii: haematol.2018.212563. doi: 10.3324/haematol.2018.212563. [Epub ahead of print]

3.

TCF4 promotes erythroid development.

In 't Hout FEM, van Duren J, Monteferrario D, Brinkhuis E, Mariani N, Westers TM, Chitu D, Nikoloski G, van de Loosdrecht AA, van der Reijden BA, Jansen JH, Huls G.

Exp Hematol. 2019 Jan;69:17-21.e1. doi: 10.1016/j.exphem.2018.10.002. Epub 2018 Oct 10.

PMID:
30315825
4.

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes.

Duetz C, Westers TM, van de Loosdrecht AA.

Pathobiology. 2019;86(1):14-23. doi: 10.1159/000490727. Epub 2018 Sep 18. Review.

5.

Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes.

van Leeuwen-Kerkhoff N, Lundberg K, Westers TM, Kordasti S, Bontkes HJ, Lindstedt M, de Gruijl TD, van de Loosdrecht AA.

Front Immunol. 2018 Jul 16;9:1619. doi: 10.3389/fimmu.2018.01619. eCollection 2018.

6.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

7.

Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes.

van Spronsen MF, Westers TM, Rozema H, Ossenkoppele GJ, Kibbelaar RE, Hoogendoorn M, van de Loosdrecht AA.

Am J Hematol. 2017 Nov;92(11):E631-E634. doi: 10.1002/ajh.24867. Epub 2017 Aug 24. No abstract available.

8.

Transcriptional profiling reveals functional dichotomy between human slan+ non-classical monocytes and myeloid dendritic cells.

van Leeuwen-Kerkhoff N, Lundberg K, Westers TM, Kordasti S, Bontkes HJ, de Gruijl TD, Lindstedt M, van de Loosdrecht AA.

J Leukoc Biol. 2017 Oct;102(4):1055-1068. doi: 10.1189/jlb.3MA0117-037R. Epub 2017 Jul 18.

PMID:
28720687
9.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
10.

Response to letter commenting on: Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Witte BI, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2017 Feb;72:269-271. doi: 10.1016/j.ejca.2016.11.029. Epub 2017 Jan 2. No abstract available.

PMID:
28057399
11.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

12.

Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia.

Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA, Sanders MA, Hoogenboezem RM, Bindels EMJ, Adisty MN, Van Strien PMH, van der Leije CS, Westers TM, Cremers EMP, Milanese C, Mastroberardino PG, van Leeuwen JPTM, van der Eerden BCJ, Touw IP, Kuijpers TW, Kanaar R, van de Loosdrecht AA, Vogl T, Raaijmakers MHGP.

Cell Stem Cell. 2016 Nov 3;19(5):613-627. doi: 10.1016/j.stem.2016.08.021. Epub 2016 Sep 22.

13.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

14.

Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs.

Chen S, Zambetti NA, Bindels EM, Kenswill K, Mylona AM, Adisty NM, Hoogenboezem RM, Sanders MA, Cremers EM, Westers TM, Jansen JH, van de Loosdrecht AA, Raaijmakers MH.

Leukemia. 2016 Sep;30(9):1938-42. doi: 10.1038/leu.2016.91. Epub 2016 Apr 25. No abstract available.

15.

Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2016 Mar;56:10-20. doi: 10.1016/j.ejca.2015.12.004. Epub 2016 Jan 19.

PMID:
26798967
16.

Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.

Cremers EMP, Westers TM, Alhan C, Cali C, Wondergem MJ, Poddighe PJ, Ossenkoppele GJ, van de Loosdrecht AA.

Eur J Cancer. 2016 Feb;54:49-56. doi: 10.1016/j.ejca.2015.11.013. Epub 2015 Dec 22.

PMID:
26720403
17.

Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.

Alhan C, Westers TM, Cremers EM, Cali C, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2016 Jul;90(4):358-67. doi: 10.1002/cyto.b.21333. Epub 2015 Dec 14.

18.

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Leukemia. 2016 Mar;30(3):658-65. doi: 10.1038/leu.2015.295. Epub 2015 Oct 27.

PMID:
26503643
19.

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

Ruben JM, Visser LL, Heinhuis KM, O'Toole T, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

PLoS One. 2015 Aug 7;10(8):e0135219. doi: 10.1371/journal.pone.0135219. eCollection 2015.

20.

Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2015 Nov;64(11):1419-27. doi: 10.1007/s00262-015-1741-1. Epub 2015 Jul 28.

21.

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Kahn JD, Chamuleau ME, Westers TM, Van de Ven PM, van Dreunen L, van Spronsen M, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2015 Jun;100(6):e220-2. doi: 10.3324/haematol.2014.116657. Epub 2015 Mar 6. No abstract available.

22.

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Cremers EM, Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Best Pract Res Clin Haematol. 2015 Mar;28(1):14-21. doi: 10.1016/j.beha.2014.11.003. Epub 2014 Nov 11. Review.

PMID:
25659726
23.

In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD.

Oncoimmunology. 2014 Jul 3;3(7):e946360. eCollection 2014.

24.

Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.

Oelschlaegel U, Westers TM, Mohr B, Kramer M, Parmentier S, Sockel K, Thiede C, Bornhäuser M, Ehninger G, van de Loosdrecht AA, Platzbecker U.

Haematologica. 2015 Mar;100(3):e93-6. doi: 10.3324/haematol.2014.115725. Epub 2014 Nov 25. No abstract available.

25.

High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Br J Haematol. 2014 Oct;167(1):100-9. doi: 10.1111/bjh.12994. Epub 2014 Jun 30.

PMID:
24976502
26.

ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.

Wiggers TG, Westra G, Westers TM, Abbes AP, Strunk A, Kuiper-Kramer E, Poddighe P, van de Loosdrecht AA, Chamuleau ME.

Cytometry B Clin Cytom. 2014 Jul;86(4):280-7. doi: 10.1002/cyto.b.21132. Epub 2013 Oct 8.

27.

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.

Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subirá D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Béné MC.

Leukemia. 2014 Sep;28(9):1793-8. doi: 10.1038/leu.2014.191. Epub 2014 Jun 12.

PMID:
24919805
28.

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, van Ham SM, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2014 Jun;38(6):691-3. doi: 10.1016/j.leukres.2014.03.014. Epub 2014 Mar 25.

PMID:
24731748
29.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2014 May;86(3):207-15. doi: 10.1002/cyto.b.21160. Epub 2014 Jan 28.

30.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2014 Jan 15. doi: 10.1002/cytob.21160. [Epub ahead of print]

PMID:
24431028
31.

Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines.

Ruben JM, van den Ancker W, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2014 Apr;63(4):335-45. doi: 10.1007/s00262-013-1515-6. Epub 2014 Jan 3.

PMID:
24384837
32.

Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.

van den Ancker W, Wijnands PG, Ruben JM, Westers TM, Punt B, Bachas C, Ravenshorst N, van Wetering S, Kruisbeek AM, Bontkes HJ, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD.

Immunotherapy. 2013 Nov;5(11):1183-90. doi: 10.2217/imt.13.125.

PMID:
24188673
33.

ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.

Wiggers TG, Westra G, Westers TM, Abbes AP, Strunk A, Kuiper-Kramer E, Poddighe P, van de Loosdrecht AA, Chamuleau ME.

Cytometry B Clin Cytom. 2013 Oct 1. doi: 10.1002/cytob.21132. [Epub ahead of print]

34.

Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.

Ruben JM, Visser LL, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Immunotherapy. 2013 Aug;5(8):859-68. doi: 10.2217/imt.13.76. Review.

PMID:
23902555
35.

Cutting edge: flow cytometry in myelodysplastic syndromes.

van de Loosdrecht AA, Westers TM.

J Natl Compr Canc Netw. 2013 Jul;11(7):892-902. Review.

PMID:
23847222
36.

Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.

van den Ancker W, Ruben JM, Westers TM, Wulandari D, Bontkes HJ, Hooijberg E, Stam AG, Santegoets SJ, Ossenkoppele GJ, de Gruijl T, van de Loosdrecht A.

Oncoimmunology. 2013 Apr 1;2(4):e23971.

37.

Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.

Kerkhoff N, Bontkes HJ, Westers TM, de Gruijl TD, Kordasti S, van de Loosdrecht AA.

Immunotherapy. 2013 Jun;5(6):621-37. doi: 10.2217/imt.13.51. Review.

PMID:
23725285
38.

MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia.

de Leeuw DC, van den Ancker W, Denkers F, de Menezes RX, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA, Smit L.

Clin Cancer Res. 2013 Apr 15;19(8):2187-96. doi: 10.1158/1078-0432.CCR-12-3657. Epub 2013 Feb 26.

39.

A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin.

van den Ancker W, Westers TM, de Leeuw DC, van der Veeken YF, Loonen A, van Beckhoven E, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2013 Mar;84(2):114-8. doi: 10.1002/cyto.b.21072. Epub 2013 Jan 16.

40.

Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.

Abouyahya I, Alhan C, Westers TM, te Boekhorst PA, Kappers-Klunne MC, Coenen JL, Heyning FH, Huls GA, de Wolf JT, Imholz AL, Koene HR, Veth G, de Kruijf EJ, Muus P, Planken EV, Segeren CM, Vasmel WL, van der Velden AM, Velders GA, Koedam J, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Lymphoma. 2013 Apr;54(4):874-7. doi: 10.3109/10428194.2012.728702. Epub 2012 Sep 28. No abstract available.

PMID:
22971215
41.

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.

Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Review.

PMID:
22916713
42.

Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.

Bontkes HJ, Ruben JM, Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2012 Jul;36(7):921-30. doi: 10.1016/j.leukres.2012.03.026. Epub 2012 Apr 14.

43.

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, van de Loosdrecht AA, Ogata K.

Haematologica. 2012 Aug;97(8):1209-17. doi: 10.3324/haematol.2011.048421. Epub 2012 Feb 7.

44.

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA.

Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6.

PMID:
22307178
45.

Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS.

Westers TM, van der Velden VH, Alhan C, Bekkema R, Bijkerk A, Brooimans RA, Cali C, Dräger AM, de Haas V, Homburg C, de Jong A, Kuiper-Kramer PE, Leenders M, Lommerse I, te Marvelde JG, van der Molen-Sinke JK, Moshaver B, Mulder AB, Preijers FW, Schindhelm RK, van der Sluijs A, van Wering ER, Westra AH, van de Loosdrecht AA; Working Party on Flow Cytometry in MDS of Dutch Society of Cytometry (NVC).

Leuk Res. 2012 Apr;36(4):422-30. doi: 10.1016/j.leukres.2011.09.015. Epub 2011 Oct 6.

PMID:
21982641
46.

Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.

van Luijn MM, Westers TM, Chamuleau ME, van Ham SM, Ossenkoppele GJ, van de Loosdrecht AA.

Am J Pathol. 2011 Nov;179(5):2157-61. doi: 10.1016/j.ajpath.2011.07.027. Epub 2011 Sep 9.

47.

Flow cytometry in myelodysplastic syndromes: ready for translation into clinical practice.

van de Loosdrecht AA, Westers TM.

Leuk Res. 2011 Jul;35(7):850-2. doi: 10.1016/j.leukres.2011.03.030. Epub 2011 May 6. No abstract available.

PMID:
21529940
48.

Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.

Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ.

Br J Haematol. 2011 Jun;153(5):568-81. doi: 10.1111/j.1365-2141.2011.08683.x. Epub 2011 Apr 13. Review.

PMID:
21488861
49.

Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.

Westers TM, van den Ancker W, Bontkes HJ, Janssen JJ, van de Loosdrecht AA, Ossenkoppele GJ.

Immunotherapy. 2011 Apr;3(4):569-76. doi: 10.2217/imt.11.3.

PMID:
21463196
50.

Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: mixed phenotype acute leukemia with erythrophagocytosis.

de Leeuw DC, van den Ancker W, Westers TM, Loonen AH, Bhola SL, Ossenkoppele GJ, van de Loosdrecht AA.

Leuk Res. 2011 May;35(5):693-6. doi: 10.1016/j.leukres.2011.01.024. Epub 2011 Feb 21. No abstract available.

PMID:
21334744

Supplemental Content

Loading ...
Support Center